Strides Pharma awaiting govt nod for Favipiravir, says CEO R Ananthanarayanan

"Our focus is ensuring that we are able to get approvals for all the
necessary studies and data in India. We will be able to provide the
drug once the Indian approvals come through. This is our main
bottleneck now," said R Ananthanarayanan.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/strides-pharma-awaiting-govt-nod-for-favipiravir-says-ceo-r-ananthanarayanan/articleshow/75463029.cms

Comments

Popular posts from this blog

Lupin, Aurobindo units recall products in US market

MAHE Manipal Research Fellow Jobs – Biotech / Mol Bio / Microbiology Apply

Data Analyst Jobs – Life Sciences Apply at Cognizant